Efficacy and Cardiovascular Safety of Insulins.

Efficacy and Cardiovascular Safety of Insulins. Curr Drug Saf. 2020 Nov 05;: Authors: Fernandez CJ, Radhakrishnan C Abstract Insulin is a lifesaving drug in patients with type 1 diabetes mellitus. Many type 2 diabetes mellitus patients will eventually require insulin. The rapid-acting and long-acting insulin analogues (RAIAs and LAIAs) have a pharmacological profile that closely mimic normal human physiology when compared to Neutral Protamine Hagedorn (NPH) insulin and regular human insulin, respectively. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) were found to have a proven cardiovascular safety. They are preferred over insulin in many recent guidelines. Fixed-ratio combinations of GLP-1RAs and insulin are also recommended, when either of these molecules fail to achieve glycaemic control. Despite decades of experience in using insulin, there is a debate among scientific community over the safety of exogenous insulin, especially regarding their cardiovascular safety and the risk of cancer. There is also an ongoing debate regarding the safety, even after the two long-acting insulin analogues (glargine and degludec) have proven their cardiovascular non-inferiority. Drugs with proven safety are often preferred in patient with pre-existing cardiovascular disease or at high risk of cardiovascular disease. In this review we will critically analyse these efficacy and safety issues related to insulin molecules to help in clinical d...
Source: Current Drug Safety - Category: Drugs & Pharmacology Authors: Tags: Curr Drug Saf Source Type: research